Madison Avenue Partners, LP: INDIVIOR PHARMCEUTICALS INC (INDV): Quarterly 13F Position History
As of Q1 2026, Madison Avenue Partners, LP reported 4,315,162 shares of INDIVIOR PHARMCEUTICALS INC (INDV), worth $131.5M and representing 5.7% of its 13F equity book. Quarter-over-quarter share count change: 1,965,340 (-31.3%) . The position first appeared in Q2 2023 and has been disclosed across 12 13F-HR filings in Pactolio's tracked window.
- 4,315,162Shares Held (Latest Filing)
- $131.5MReported Market Value (Latest Filing)
- 5.7%Portfolio Weight (% of 13F Equity Book)
- 1,965,340Quarter-over-Quarter Share Change
- -$93.8MQuarter-over-Quarter Value Change
- 7,922,178Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 12 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 4,315,162 | 1,965,340 | -31.3% | $131.5M | 5.7% | $30.5 |
| Q4 2025 | 6,280,502 | 183,083 | -2.8% | $225.3M | 9.7% | $35.9 |
| Q3 2025 | 6,463,585 | 1,458,593 | -18.4% | $155.8M | 9.3% | $24.1 |
| Q2 2025 | 7,922,178 | +130,089 | +1.7% | $116.8M | 7.8% | $14.7 |
| Q1 2025 | 7,792,089 | +4,118,663 | +112.1% | $74.3M | 6.3% | $9.5 |
| Q4 2024 | 3,673,426 | 287,346 | -7.3% | $45.7M | 4.8% | $12.4 |
| Q3 2024 | 3,960,772 | +3,737,340 | +1672.7% | $38.6M | 3.6% | $9.8 |
| Q2 2024 | 223,432 | +60,537 | +37.2% | $3.6M | 0.5% | $16.1 |
| Q1 2024 | 162,895 | +90,640 | +125.4% | $3.5M | 0.6% | $21.4 |
| Q4 2023 | 72,255 | +33,168 | +84.9% | $1.1M | 0.2% | $15.3 |
| Q3 2023 | 39,087 | +27,887 | +249.0% | $901.7K | 0.1% | $23.1 |
| Q2 2023 | 11,200 | — | — | $266.6K | 0.1% | $23.8 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Madison Avenue Partners, LP first disclose a INDV position in 13F-HR filings?
Madison Avenue Partners, LP first reported INDIVIOR PHARMCEUTICALS INC (INDV) on its 13F-HR filing for the period ending 2023-06-30 (Q2 2023). The position has appeared on 12 reported quarters within Pactolio's tracked window.
What was Madison Avenue Partners, LP's most recent quarter-over-quarter share-count change in INDV?
Between Q4 2025 and Q1 2026, Madison Avenue Partners, LP reduced its INDV position by 1,965,340 shares (-31.3%), leaving 4,315,162 shares at a market value of $131.5M.
Does the implied price-per-share represent Madison Avenue Partners, LP's cost basis in INDV?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.